AVITA MEDICAL INC (RCEL) Fundamental Analysis & Valuation

NASDAQ:RCEL • US05380C1027

4.75 USD
-0.03 (-0.63%)
At close: Mar 6, 2026
4.75 USD
0 (0%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RCEL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Taking everything into account, RCEL scores 1 out of 10 in our fundamental rating. RCEL was compared to 519 industry peers in the Biotechnology industry. RCEL has a bad profitability rating. Also its financial health evaluation is rather negative. RCEL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. RCEL Profitability Analysis

1.1 Basic Checks

  • RCEL had negative earnings in the past year.
  • In the past year RCEL has reported a negative cash flow from operations.
  • RCEL had negative earnings in each of the past 5 years.
  • In the past 5 years RCEL always reported negative operating cash flow.
RCEL Yearly Net Income VS EBIT VS OCF VS FCFRCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • RCEL's Return On Assets of -76.19% is on the low side compared to the rest of the industry. RCEL is outperformed by 65.38% of its industry peers.
Industry RankSector Rank
ROA -76.19%
ROE N/A
ROIC N/A
ROA(3y)-45.47%
ROA(5y)-41.71%
ROE(3y)-492.75%
ROE(5y)-311.85%
ROIC(3y)N/A
ROIC(5y)N/A
RCEL Yearly ROA, ROE, ROICRCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 500 -500 -1K

1.3 Margins

  • With an excellent Gross Margin value of 84.81%, RCEL belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
  • In the last couple of years the Gross Margin of RCEL has grown nicely.
  • RCEL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
RCEL Yearly Profit, Operating, Gross MarginsRCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. RCEL Health Analysis

2.1 Basic Checks

  • RCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • RCEL has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for RCEL has been increased compared to 5 years ago.
  • Compared to 1 year ago, RCEL has a worse debt to assets ratio.
RCEL Yearly Shares OutstandingRCEL Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M
RCEL Yearly Total Debt VS Total AssetsRCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • RCEL has an Altman-Z score of -8.87. This is a bad value and indicates that RCEL is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of RCEL (-8.87) is worse than 70.19% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.87
ROIC/WACCN/A
WACC9.57%
RCEL Yearly LT Debt VS Equity VS FCFRCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • RCEL has a Current Ratio of 0.67. This is a bad value and indicates that RCEL is not financially healthy enough and could expect problems in meeting its short term obligations.
  • RCEL's Current ratio of 0.67 is on the low side compared to the rest of the industry. RCEL is outperformed by 89.04% of its industry peers.
  • A Quick Ratio of 0.55 indicates that RCEL may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.55, RCEL is doing worse than 89.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.67
Quick Ratio 0.55
RCEL Yearly Current Assets VS Current LiabilitesRCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. RCEL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 26.78% over the past year.
EPS 1Y (TTM)26.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-4.29%

3.2 Future

  • RCEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.76% yearly.
  • RCEL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.48% yearly.
EPS Next Y49.68%
EPS Next 2Y34.59%
EPS Next 3Y57.48%
EPS Next 5Y32.76%
Revenue Next Year19.9%
Revenue Next 2Y33.92%
Revenue Next 3Y47.36%
Revenue Next 5Y36.48%

3.3 Evolution

RCEL Yearly Revenue VS EstimatesRCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
RCEL Yearly EPS VS EstimatesRCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

1

4. RCEL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RCEL. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCEL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCEL Price Earnings VS Forward Price EarningsRCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCEL Per share dataRCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RCEL's earnings are expected to grow with 57.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.59%
EPS Next 3Y57.48%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RCEL Dividend Analysis

5.1 Amount

  • No dividends for RCEL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RCEL Fundamentals: All Metrics, Ratios and Statistics

AVITA MEDICAL INC

NASDAQ:RCEL (3/6/2026, 8:00:02 PM)

After market: 4.75 0 (0%)

4.75

-0.03 (-0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-13
Earnings (Next)05-06
Inst Owners15.86%
Inst Owner Change-5.08%
Ins Owners1.37%
Ins Owner Change19.38%
Market Cap145.49M
Revenue(TTM)N/A
Net Income(TTM)-48.55M
Analysts80
Price Target6.32 (33.05%)
Short Float %12.4%
Short Ratio15.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-54.51%
Min EPS beat(2)-58.8%
Max EPS beat(2)-50.22%
EPS beat(4)1
Avg EPS beat(4)-35.89%
Min EPS beat(4)-58.8%
Max EPS beat(4)0.41%
EPS beat(8)2
Avg EPS beat(8)-27.63%
EPS beat(12)4
Avg EPS beat(12)-19.86%
EPS beat(16)8
Avg EPS beat(16)-6.57%
Revenue beat(2)0
Avg Revenue beat(2)-14.07%
Min Revenue beat(2)-20.13%
Max Revenue beat(2)-8.01%
Revenue beat(4)0
Avg Revenue beat(4)-14.13%
Min Revenue beat(4)-20.13%
Max Revenue beat(4)-8.01%
Revenue beat(8)1
Avg Revenue beat(8)-7.78%
Revenue beat(12)5
Avg Revenue beat(12)-4.45%
Revenue beat(16)8
Avg Revenue beat(16)-0.38%
PT rev (1m)-10.14%
PT rev (3m)-15.07%
EPS NQ rev (1m)7.69%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-20.03%
Revenue NQ rev (1m)-1.96%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.43%
Revenue NY rev (3m)-5.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS2.37
BVpS-0.22
TBVpS-0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -76.19%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.81%
FCFM N/A
ROA(3y)-45.47%
ROA(5y)-41.71%
ROE(3y)-492.75%
ROE(5y)-311.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
F-Score3
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 160.07%
Cap/Sales 4.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.67
Quick Ratio 0.55
Altman-Z -8.87
F-Score3
WACC9.57%
ROIC/WACCN/A
Cap/Depr(3y)370.65%
Cap/Depr(5y)291.06%
Cap/Sales(3y)6.11%
Cap/Sales(5y)5.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.64%
EPS Next Y49.68%
EPS Next 2Y34.59%
EPS Next 3Y57.48%
EPS Next 5Y32.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-4.29%
Revenue Next Year19.9%
Revenue Next 2Y33.92%
Revenue Next 3Y47.36%
Revenue Next 5Y36.48%
EBIT growth 1Y29.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.51%
EBIT Next 3Y21.46%
EBIT Next 5Y21.51%
FCF growth 1Y-16.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.62%
OCF growth 3YN/A
OCF growth 5YN/A

AVITA MEDICAL INC / RCEL FAQ

What is the ChartMill fundamental rating of AVITA MEDICAL INC (RCEL) stock?

ChartMill assigns a fundamental rating of 1 / 10 to RCEL.


What is the valuation status of AVITA MEDICAL INC (RCEL) stock?

ChartMill assigns a valuation rating of 1 / 10 to AVITA MEDICAL INC (RCEL). This can be considered as Overvalued.


Can you provide the profitability details for AVITA MEDICAL INC?

AVITA MEDICAL INC (RCEL) has a profitability rating of 1 / 10.